Johanna B. Svensson
Goeteborg, O, Sweden
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 54 publications
Patient Survival and Its Relation to Tumor Absorbed Dose in [177Lu]Lu-DOTATATE Therapy of Neuroendocrine Tumors.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: December 07, 2025
Molecular-clinical characteristics and treatment outcomes in 163 metastatic colorectal neuroendocrine carcinomas with a comparison to colorectal adenocarcinomas.
Journal: International journal of cancer
Published: September 10, 2025
Correction: Characteristics and treatment outcome in a prospective cohort of 639 advanced high-grade digestive neuroendocrine neoplasms (NET G3 and NEC). The NORDIC NEC 2 study.
Journal: British journal of cancer
Published: July 14, 2025
Modelling the relative precision of whole-kidney dosimetry in molecular radiotherapy using a power law approach.
Journal: Radiation protection dosimetry
Published: June 27, 2025
High baseline PD-1+ CD8 T Cells and TIGIT+ CD8 T Cells in circulation associated with response to PD-1 blockade in patients with non-small cell lung cancer.
Journal: Cancer immunology, immunotherapy : CII
Published: March 17, 2025
Gain of chromosome 17 is an early genetic abnormality in neuroblastoma with PPM1D emerging as a strong candidate oncogene driving tumor progression.
Journal: Cancer letters
Published: February 25, 2025
Comparative analysis of whole-genome sequencing of tumor and cfDNA in a neuroblastoma patient: a case report.
Journal: Frontiers in oncology
Published: January 31, 2025
Characteristics and treatment outcome in a prospective cohort of 639 advanced high-grade digestive neuroendocrine neoplasms (NET G3 and NEC). The NORDIC NEC 2 study.
Journal: British journal of cancer
Published: January 27, 2025
Comprehensive genetic variant analysis reveals combination of KRAS and LRP1B as a predictive biomarker of response to immunotherapy in patients with non-small cell lung cancer.
Journal: Journal of experimental & clinical cancer research : CR
Published: December 22, 2024
177Lu-DOTATATE in Combination with PARP Inhibitor Olaparib Is Feasible in Patients with Somatostatin-Positive Tumors: Results from the LuPARP Phase I Trial.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: October 02, 2024
Last Updated: 09/26/2026